Nektar Therapeutics Stock News

Clinical-stage biotech Nektar Therapeutics (NKTR) is trading higher on Tuesday after losing over half of its market cap yesterday in reaction to its failure to reach the main goals in…

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the fourth quarter, compared

Tuesday afternoon''s top analyst upgrades and downgrades included Coupa Software, GoodRx, Mosaic and Nektar Therapeutics.

Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.

Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.

Wells Fargo cut the price target on Coupa Software Incorporated (NYSE: LPI) from $190 to $80. Laredo Petroleum shares fell 29.8% to $63.10 in pre-market trading. Credit Suisse raised HollyFrontier

Markets edged higher to start off Tuesday, as West Texas Intermediate crude slid below the $100 mark.

Fintech stocks fell on reports of a troubled securities sale from AFRM. BRK.A tested the $500K mark and hit a new high. GME fell to a new low. NKTR plunged on clinical data. TRQ rallied.

A clinical trial readout involving the company's lead candidate didn't produce the results investors were hoping for.

A clinical trial readout involving the company''s lead candidate didn''t produce the results investors were hoping for.

Bristol Myers Squibb Co (NYSE: BMY ) and Nektar Therapeutics (NASDAQ: NKTR ) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of bempegaldesleukin combined with Opdivo (nivolumab) in previously untreated unresectable or metastatic melanoma patients. The review by an independent Data Monitoring Committee (DMC) suggested that the study did … Full story available on Benzinga.com

Upgrades Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE:ENVA) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter, compared to $2.39 in

Upgrades Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE: ENVA ) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter, compared to $2.39 in the year-ago quarter. The stock has a 52-week-high of $47.88 and a 52-week-low of $30.04. At the end of the last trading period, Enova International closed at $33.50. Seaport Global upgraded the previous rating for Helmerich & Payne Inc (NYSE: HP ) from Neutral to Buy. For the first quarter, Helmerich & Payne had an EPS of $0.45, compared to year-ago quarter EPS of $0.82. The stock has a 52-week-high of $45.40 and a 52-week-low of $20.93. At the end of the last trading period, Helmerich & Payne closed at $41.88. According to Berenberg, the prior rating for Deutsche Bank AG (NYSE: DB ) was changed from Sell to Hold. For the fourth quarter, Deutsche Bank had an EPS of $0.14, compared to year-ago quarter EPS of $0.08. The stock has a 52-week-high of $16.70 and a 52-week-low of $9.46. At the end of the last trading period, Deutsche Bank closed at $10.25.

Clinical-stage biotech Nektar Therapeutics (NKTR) continues to trade sharply lower on Monday after the company announced its lead candidate bempegaldesleukin failed to meet the main…

Adding Nektar''s most drug to Bristol Myers'' Opdivo didn''t improve outcomes for melanoma patients — leading NKTR stock to crash Monday.